Antimicrobial resistance

Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance

Retrieved on: 
Tuesday, June 21, 2022
Progress, Science, Map, Global health, World, Coronavirus Scientific Advisory Board (Turkey), Antimicrobial resistance, Merck, Clinical trial, MD, University, Health, World Health Organization, First Nations in Ontario, Viatris, CDC, HIV Medicine, Infection, University of Cape Town, Climate, Life, Division, United Nations General Assembly, GRAM, Trust law, Death, AMR, Shionogi, Mental health, Industry, Korea Disease Control and Prevention Agency, Groote Schuur Hospital, Twitter, Center, Johnson & Johnson, Doctor of Philosophy, Public health, UNGA, COVID-19, Makerere University, HIV, Nuffield Department of Population Health, Outline of health sciences, Risk, Makerere University College of Health Sciences, GSK, Research, University of Washington Department of Global Health, Pfizer, United Nations, Wellcome Trust, Vaccine, Pharmaceutical industry, Wellcome

CAMBRIDGE, Mass., June 21, 2022 /PRNewswire/ -- The Antimicrobial Resistance Register, unveiled today by the nonprofit organization Vivli, makes it possible for biopharmaceutical companies to share susceptibility data on infection causing pathogens for the first time ever in one online platform, marking a critical step in combating the growing global health threat of antimicrobial resistance. With the active participation from leading pharmaceutical and biotech enterprises, researchers will be able to use the AMR Register to translate masses of antimicrobial resistance surveillance data into meaningful action that saves lives and preserves antibiotics for future generations.

Key Points: 
  • According to latest figures from the GRAM report, almost 5 million people died worldwide with an antimicrobial resistant infection.
  • If left unchecked, the scale of antimicrobial resistance will quickly outpace what we have experienced with COVID-19, with deaths rising to 10 million per year by 2050, according to the United Nations.
  • "Our understanding of how to control antimicrobial resistant infections and how best to protect human health hinges on better access to surveillance data.
  • Data sharing initiatives include the Antimicrobial Resistance Register for AMR surveillance data and the Vivli Platform for clinical trial data.

Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system

Retrieved on: 
Thursday, May 12, 2022
European Investment Bank, Microbiology, Research, Investment banking, Infection, EUR, Patient, Policy, Goal, Bacteria, Antimicrobial resistance, Technology, Union, EIB, AMR, Diagnosis, CEO, Pharmaceutical industry, EU

REHOVOT, Israel, May 12, 2022 /PRNewswire/ -- Research and development of fully automated testing of bacteria and infectious diseases by POCARED Diagnostics will be accelerated by EUR 22 million of European Investment Bank specialized venture debt formally announced earlier today.

Key Points: 
  • "We are honoured to be selected by the European Investment Bank as the first Israeli medtech company to be supported by the Infectious Disease Financing Facility.
  • The investment will allow POCARED to significantly accelerate development of our diagnostic system and complete the preparations for its clinical trials.
  • We are pleased to provide EUR 22 million of new venture debt financing to enhance POCARED's development of rapid microbiology diagnostics solution.
  • POCARED Diagnostics Ltd, is an in-vitro diagnostic and pre-analytics company utilizing cutting edge technologies to deliver next generation platforms.

Pocared Diagnostics, an Israeli rapid infectious diseases diagnostics leader, secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system

Retrieved on: 
Thursday, May 12, 2022
European Investment Bank, Microbiology, Research, Investment banking, Infection, EUR, Patient, Policy, Goal, Bacteria, Antimicrobial resistance, Technology, Union, EIB, AMR, Diagnosis, CEO, Pharmaceutical industry, EU

REHOVOT, Israel, May 12, 2022 /PRNewswire/ -- Research and development of fully automated testing of bacteria and infectious diseases by POCARED Diagnostics will be accelerated by EUR 22 million of European Investment Bank specialized venture debt formally announced earlier today.

Key Points: 
  • "We are honoured to be selected by the European Investment Bank as the first Israeli medtech company to be supported by the Infectious Disease Financing Facility.
  • The investment will allow POCARED to significantly accelerate development of our diagnostic system and complete the preparations for its clinical trials.
  • We are pleased to provide EUR 22 million of new venture debt financing to enhance POCARED's development of rapid microbiology diagnostics solution.
  • POCARED Diagnostics Ltd, is an in-vitro diagnostic and pre-analytics company utilizing cutting edge technologies to deliver next generation platforms.

Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines Against Serious Bacterial Threats

Retrieved on: 
Tuesday, April 19, 2022
Biotechnology, Infectious Diseases, Other Health, Health, Pharmaceutical, Protein, CEO, Infection, MBA, United States Air Force Scientific Advisory Board, Research, Enzyme, Science, Entrepreneurship, Doctor of Philosophy, Novartis, Vaccine, Engineering, MedImmune, Policy, Bioconjugation, Industry, Tobacco Products Scientific Advisory Committee, Biotechnology industry in China, Antimicrobial resistance, Pharmaceutical industry

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck.

Key Points: 
  • Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck.
  • The research team will be led by Christian Harding, Ph.D., Chief Scientific Officer and Co-Founder of Omniose.
  • Omniose combines great science with a dedicated team on a mission to protect people from serious bacterial infections, said Timothy Cooke, CEO.
  • Our approach greatly expands the universe of bacterial targets that can be addressed by bioconjugate vaccines.

Professor Shabir Madhi joins GHC3 Talks to discuss Omicron

Retrieved on: 
Tuesday, December 21, 2021
Center, AMR, Business development, Antimicrobial resistance, University of the Witwatersrand, Public sector, Covaxin, Public health, Ethics, University, Interview, Travel, COVID-19, Solution, Emory University, Lead, Global health, COVID, Research, GLOBE, Private sector, Pharmaceutical industry, Omicron

Special guest Professor Shabir Madhi of the University of the Witwatersrand in Johannesburg, South Africa joined GHC3 Talks host Dr.

Key Points: 
  • Special guest Professor Shabir Madhi of the University of the Witwatersrand in Johannesburg, South Africa joined GHC3 Talks host Dr.
  • Rob Breiman to discuss what we do and dont know about the Omicron variant so far.
  • Professor Madhi described the pioneering science and research on COVID-19 conducted in South Africa but also the challenges faced by the region.
  • Professor Madhi explained, Imposing a travel ban on a handful of countries in Southern Africa does not reduce your chances of importing the virus.

OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

Retrieved on: 
Tuesday, December 14, 2021
Sequence, Database, Hospital, Solution, Antimicrobial resistance, U.S. Securities and Exchange Commission, Infection, NGS, Nadine Opgen-Rhein, Securities Exchange Act of 1934, Personal Data Privacy and Security Act of 2009, P, Growth, Genome, Public health, Genetics, Private Securities Litigation Reform Act, Nasdaq, AST, COVID-19, Securities Act of 1933, Ares, Adoption, Microbiology, CEO, Goal, Artificial intelligence, Machine learning, Shredding (disassembling genomic data), INT, Security (finance), Marker beacon, AMR, Whole genome sequencing, Use, GLOBE, Informatics, Analysis, Precision medicine, Technology, Phase II, Fine chemical, Pharmaceutical industry, Antibiotics, MD, Reg Rattey

During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.

Key Points: 
  • During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.
  • ARESdb is central to our development of AI-powered applications for AMR prediction stated Dr.Arne Materna, CEO of Ares Genetics.
  • Ares Genetics intends to further increase the value of ARESdb and grow its contents in the coming months and years through strategic collaborations with external partners and by supporting clinical trials conducted by its affiliates at OpGen.
  • This press release includes statements regarding Ares Genetics strategic expansion of ARESdb and certain of its related collaboration arrangements.

HealthTrackRx Offers a Menu of Testing Options for Respiratory Pathogens to Help Clinicians Get to the Right Answers Faster

Retrieved on: 
Thursday, December 16, 2021
LinkedIn, Solution, CDC, FDA, PCR, Adenoviridae, Infection, Doctor of Philosophy, Population, Health, Public health, World, Urinary tract infection, COVID-19, RVP, Antimicrobial stewardship, Antimicrobial resistance, Taiwan Centers for Disease Control, Work, World Health Organization, Korea Disease Control and Prevention Agency, Patient, AMR, WHO, Fever, RSV, Viral pneumonia, LDT, Technology, PIV, Pharmaceutical industry, Vaccine, Omicron

DENTON, Texas, Dec. 16, 2021 /PRNewswire/ --HealthTrackRx, the leading polymerase chain reaction (PCR) testing lab, provides clinicians with a menu of respiratory testing solutions focused on diagnostic speed and accuracy.

Key Points: 
  • DENTON, Texas, Dec. 16, 2021 /PRNewswire/ --HealthTrackRx, the leading polymerase chain reaction (PCR) testing lab, provides clinicians with a menu of respiratory testing solutions focused on diagnostic speed and accuracy.
  • "Our proprietary PCR testing technology offers the benefits of speed and accuracy so clinicians can make better decisions faster," says Jay Reddy, PhD, Vice President of Laboratory Operations at HealthTrackRx.
  • With HealthTrackRx PCR testing, clinicians can select from a variety of menus, four of which include testing for COVID-19.
  • HealthTrackRx is the nation's leading PCR-based infectious disease laboratory, delivering industry-leading testing turnaround times to clinicians nationwide.

LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows

Retrieved on: 
Friday, September 3, 2021
Food safety, Chain reaction, Culture, Awareness, UTI, News, Veterinarian, Antimicrobial resistance, Solution, OTCQB, Master of Veterinary Science, Critical care, PCR, Conference, Doctor of Philosophy, Intention, Company, TSX Venture Exchange, SEDAR, LXG, ID, Polymerase chain reaction, Technology, Master of Science, CEO, Genetic testing, GLOBE, Vaccine, Risk management

Beginning this September 7th and through September 26th, the MiQLab will be featured at some of the veterinary industrys landmark events in Las Vegas, Nashville, and San Antonio.

Key Points: 
  • Beginning this September 7th and through September 26th, the MiQLab will be featured at some of the veterinary industrys landmark events in Las Vegas, Nashville, and San Antonio.
  • Additionally, LexaGenes senior scientist, Dr. Eric DiBasio, MSc, PhD, will present a poster describing a study using LexaGenes MiQLab Bacterial and AMR Test for rapid detection of UTI pathogens.
  • LexaGene will showcase its MiQLab to one of the largest regional veterinary audiences and will have a podium opportunity.
  • The MiQLab system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours.

Biomeme & Predigen Merge to Enable Point-of-Care Delivery of Host Response Tests That Address Critical Unmet Needs in Healthcare

Retrieved on: 
Thursday, August 26, 2021
Duke University, Degenerative disease, Time-invariant system, United States Department of Veterans Affairs, COVID, Infection, University, PCR, Bacteria, Software, City, Real-time, Acquisition, Department of Defense Cyber Crime Center, Biomarker, United States Department of Defense, Research, Pharmacy, Doctor of Philosophy, Chemistry, Machine learning, Hospital, Precision medicine, National, Antimicrobial resistance, AMR, Patient, Partnership, United States Department of Homeland Security, Nursing, Solution, CEO, NIH, Association of Public Health Laboratories, Challenge, National Institutes of Health, School, DHS, COVID-19, Department, Technology, Gene expression, Medicine, Medical device, Vaccine, Online shopping

Predigen also has signatures for sepsis diagnosis, sepsis risk stratification, and a pipeline of biomarkers for non-infectious diseases.

Key Points: 
  • Predigen also has signatures for sepsis diagnosis, sepsis risk stratification, and a pipeline of biomarkers for non-infectious diseases.
  • That need still exists and it is a significant market opportunity that requires accurate, near-patient and rapid-result performance capabilities.
  • Combining Predigen's tests with Biomeme's portable gold-standard platforms will deliver a better diagnostic solution for use in diverse healthcare settings.
  • Over the past decade, Predigen has pioneered the use of host response to diagnose and manage disease, and as a result has developed robust host gene expression signatures that address unmet needs in medicine.

Klick Health and Lakeridge Health Unveil Free Drug Dosage Calculator to Fight Antibiotic-Resistant Bacterial Infections

Retrieved on: 
Wednesday, August 4, 2021
Data Management, Other Science, Medical Supplies, Technology, Research, Managed Care, General Health, Surgery, Pharmaceutical, Other Communications, Marketing, Human Resources, Hospitals, Advertising, Communications, Consulting, Professional Services, Software, Health, Science, Articles, Health sciences, Chemistry, Click, Klick, Lakeridge Health, Vancomycin, Antimicrobial resistance, Lakeridge Health, Klick Health, Klick Group, LAKERIDGE HEALTH, KLICK HEALTH, KLICK GROUP

Today, Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.

Key Points: 
  • Today, Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.
  • The tool, VancoCalc , which has been in use at Lakeridge Health since December 2020, is available for free at www.VancoCalc.com .
  • We are proud to collaborate with Lakeridge Health on this important healthcare innovation, said Klick Medical R&D Scientist and project lead Anirudh Thommandram.
  • The Klick Group of companies Klick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs is an ecosystem of brilliant talent collectively working to maximize their people and clients full potential.